DICE - Dual mTorc Inhibition in advanced/recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear-cell, endometrioid and high-grade serous type, and carcinosarcoma)
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
You may be able to take part in this clinical trial if you have:
- ovarian, fallopian tube or primary peritoneal cancer of clear-cell, endometrioid or high-grade serous type, or a carcinosarcoma.
- had chemotherapy previously, but the cancer is resistant to platinum chemotherapy. This means the cancer has grown or come back within six months of completing carboplatin or cisplatin chemotherapy.
This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.
About the trial
This study is looking at using a drug called TAK228 (new drug) in combination with paclitaxel (a standard chemotherapy drug) to see if it's a more effective way of treating ovarian cancer.
The drugs involved in this trial are:
- TAK228 (new drug) – a drug that is thought to interfere with cell growth and may slow or stop cancer cells from dividing. It's given as a tablet.
- Paclitaxel – a standard chemotherapy drug used to treat ovarian cancer. It's given as an intravenous infusion (a drip into the vein).
If you were to take part in this trial, you'd be randomised to receive paclitaxel on its own or paclitaxel and TAK228.
You'd be monitored throughout the trial to see how your cancer is responding to treatment and to learn more about the side effects of adding TAK228 to paclitaxel, and how these compare to paclitaxel on its own.
The study will also look at DNA to try and find 'biomarkers'. In cancer, a biomarker is anything in the body that can be used to measure or predict the activity of the cancer or the effects of treatment. This will help researchers to understand:
- which people may benefit from receiving TAK228 and paclitaxel in future.
- how differences in the genetic makeup of the cancer may influence the way women respond to or develop side effects from TAK228 when it's given in combination with paclitaxel.
- in which women these drugs might be most effective and safe to use.
